An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

NCT05225844 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Cancer
Immunotherapy
Targeted Therapy

Interventions

DRUG: Camrelizumab
DRUG: Apatinib Mesylate

Sponsor

Harbin Medical University